The National Institute for Health and Care Excellence (NICE) has issued a Final Draft Guidance (FDG) recommending GSK’s Omjjara (momelotinib) for myelofibrosis- 15 February 2024
US biopharma Citius Pharmaceuticals has announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for L 15 February 2024
US biopharma Merrimack Pharmaceuticals has revealed plans to dissolve and hand out cash to shareholders from a newly-announced milestone payment that the compan 15 February 2024
US oncology company G1 Therapeutics was hoping for a positive interim analysis in its pivotal Phase III of trilaciclib alongside gemcitabine and carboplatin for 14 February 2024
Foghorn Therapeutics has announced that its partner, Eli Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development. 12 February 2024
UK-based Poolbeg Pharma has announced that research conducted on its behalf confirms a market opportunity of at least $10 billon for POLB 001 in cancer immunoth 12 February 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.